Lothar Kanz
The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
Bilich T, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper J, Klein R, Kohlbacher O, Kanz L, Rammensee H, Stevanovic S, Brümmendorf T, Schemionek M, Rieth J, Nelde A, Bichmann L, Roerden M, Salih H, Kowalewski D, Schuster H, Tsou C, Marcu A, Neidert M, Lübke M, Walz J. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 2018; 133:550-565.
Dec 10, 2018The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
Dec 10, 2018Blood 2018; 133:550-565
Bilich Tatjana, Vucinic Vladan, Niederwieser Dietger, Bauer Jens, Märklin Melanie, Peper Janet K, Klein Reinhild, Kohlbacher Oliver, Kanz Lothar, Rammensee Hans-Georg, Stevanovic Stefan, Brümmendorf Tim H, Schemionek Mirle, Rieth Jonas, Nelde Annika, Bichmann Leon, Roerden Malte, Salih Helmut R, Kowalewski Daniel J, Schuster Heiko, Tsou Chih-Chiang, Marcu Ana, Neidert Marian Christoph, Lübke Maren, Walz Juliane S
Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia. Oncotarget 2018; 9:11876-11882.
Jan 31, 2018Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBFβ-MYH11 leukemia
Jan 31, 2018Oncotarget 2018; 9:11876-11882
Kampa-Schittenhelm Kerstin, Vogel Wichard, Bonzheim Irina, Fend Falko, Horger Marius, Kanz Lothar, Soekler Martin, Schittenhelm Marcus
A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens
Backert L, Stevanovic S, Rammensee H, Weisel K, Kohlbacher O, Salih H, Kanz L, Niederwieser D, Vucinic V, Brümmendorf T, Schemionek M, Neidert M, Berlin C, Schuster H, Walz S, Kowalewski D, Walz J. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens. Oncotarget 2017; 8:43915-43924.
Jul 4, 2017A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens
Jul 4, 2017Oncotarget 2017; 8:43915-43924
Backert Linus, Stevanovic Stefan, Rammensee Hans-Georg, Weisel Katja, Kohlbacher Oliver, Salih Helmut Rainer, Kanz Lothar, Niederwieser Dietger, Vucinic Vladan, Brümmendorf Tim H, Schemionek Mirle, Neidert Marian Christoph, Berlin Claudia, Schuster Heiko, Walz Simon, Kowalewski Daniel Johannes, Walz Juliane Sarah
Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
Kampa-Schittenhelm K, Salitzky O, Akmut F, Illing B, Kanz L, Salih H, Schittenhelm M. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. BMC cancer 2016; 16:25.
Jan 16, 2016Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
Jan 16, 2016BMC cancer 2016; 16:25
Kampa-Schittenhelm Kerstin, Salitzky Olaf, Akmut Figen, Illing Barbara, Kanz Lothar, Salih Helmut Rainer, Schittenhelm Marcus
Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring H, Weisel K. Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol 2011; 91:729-735.
Dec 15, 2011Extracorporeal light chain elimination: high cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury.
Dec 15, 2011Ann Hematol 2011; 91:729-735
Heyne Nils, Denecke Barbara, Guthoff Martina, Oehrlein Katharina, Kanz Lothar, Häring Hans-Ulrich, Weisel Katja
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Borchmann P, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause S, Mueller R, Fuchs M, Rank A, Greil R, Haverkamp H, Diehl V, Cerny T, Markova J, Ho A, Eich H, Mueller-Hermelink H, Kanz L, Engert A. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29:4234-42.
Oct 11, 2011Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
Oct 11, 2011J Clin Oncol 2011; 29:4234-42
Borchmann Peter, Paulus Ursula, Smardova Lenka, Huber Christoph, Dörken Bernd, Nerl Christoph, Krause Stefan W, Mueller Rolf-Peter, Fuchs Michael, Rank Andreas, Greil Richard, Haverkamp Heinz, Diehl Volker, Cerny Thomas, Markova Jana, Ho Anthony D, Eich Hans-Theodor, Mueller-Hermelink Hans Konrad, Kanz Lothar, Engert Andreas
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11:1036-47.
Oct 20, 2010High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Oct 20, 2010Lancet Oncol 2010; 11:1036-47
Thiel Eckhard, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Plasswilm Ludwig, Nägele Thomas, Pietsch Torsten, Bamberg Michael, Leithäuser Malte, Mergenthaler Hans-Günther, Hundsberger Thomas, Korfel Agnieszka, Martus Peter, Kanz Lothar, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, von Toll Theda, Weller Michael
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Schittenhelm M, Bokemeyer C, Wong K, Corless C, Kanz L, Störkel S, Kurek R, Honecker F, Morich J, Harlow A, Oechsle K, Kollmannsberger C, Heinrich M. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. Mol Cancer Ther 2009; 8:481-9.
Mar 10, 2009Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer
Mar 10, 2009Mol Cancer Ther 2009; 8:481-9
Schittenhelm Marcus, Bokemeyer Carsten, Wong Kwok-Kin, Corless Christopher L, Kanz Lothar, Störkel Stephan, Kurek Raffael, Honecker Friedemann, Morich Jason, Harlow Amy, Oechsle Karin, Kollmannsberger Christian, Heinrich Michael C
Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
Horger M, Pereira P, Claussen C, Kanz L, Vonthein R, Denecke B, Driessen C. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol 2008; 81:386-96.
May 1, 2008Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters.
May 1, 2008Br J Radiol 2008; 81:386-96
Horger Marius, Pereira Philippe, Claussen Claus Detlef, Kanz Lothar, Vonthein Reinhard, Denecke Barbara, Driessen Christoph
Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
Hartmann J, Grünwald V, Kanz L, Käfer G, Pintoffl J, Meisinger I, Huober J, Horger M, Schleicher J, Mayer F, German sarcoma group. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007; 110:861-6.
Aug 15, 2007Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
Aug 15, 2007Cancer 2007; 110:861-6
Hartmann Joerg T, Grünwald Viktor, Kanz Lothar, Käfer Gabriele, Pintoffl Jan, Meisinger Ines, Huober Jens, Horger Marius, Schleicher Jan, Mayer Frank, German sarcoma group
The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen C, Driessen C. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007; 109:1617-26.
Apr 15, 2007The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
Apr 15, 2007Cancer 2007; 109:1617-26
Horger Marius, Kanz Lothar, Denecke Barbara, Vonthein Reinhard, Pereira Philippe, Claussen Claus Detlef, Driessen Christoph
Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo
Scheding S, Bergmann M, Shimosaka A, Wolff P, Driessen C, Rathke G, Jaschonek K, Brugger W, Kanz L. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 2002; 42:321-7.
Mar 1, 2002Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo
Mar 1, 2002Transfusion 2002; 42:321-7
Scheding Stefan, Bergmann Markus, Shimosaka Akihiro, Wolff Philipp, Driessen Christoph, Rathke Gisa, Jaschonek Karl, Brugger Wolfram, Kanz Lothar
Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency
Lang K, Huber S, Lang F, Fritz J, Kanz L, Scheel-Walter H, Schittenhelm M, Myssina S, Roll B, Wieder T. Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. Cell Physiol Biochem 2002; 12:365-72.
Jan 1, 2002Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency
Jan 1, 2002Cell Physiol Biochem 2002; 12:365-72
Lang Karl S, Huber Stephan M, Lang Florian, Fritz Jasmin, Kanz Lothar, Scheel-Walter Hans-Gerhard, Schittenhelm Marcus, Myssina Svetlana, Roll Benjamin, Wieder Thomas